Aldeyra Therapeutics (Nasdaq:ALDX) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ALDX 주식 개요

생명공학 회사인 알데이라 테라퓨틱스는 면역 매개 질환 치료제를 개발 및 상용화하는 기업입니다.

ALDX 기본 분석
눈송이 점수
가치 평가	4/6
미래 성장	5/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 81.6% 에서 거래

수익은 매년 63.78% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 0.9% 증가했습니다.

분석가들은 주가가 96.1% 상승할 것이라는 데 동의합니다.

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

지난 3개월간 상당한 내부자 매도

최근 3개월간 주가 변동성

Aldeyra Therapeutics, Inc. 경쟁사

Inozyme Pharma

NasdaqGS:INZY

US$325.0m

MeiraGTx Holdings

NasdaqGS:MGTX

US$329.7m

Corvus Pharmaceuticals

NasdaqGM:CRVS

US$322.1m

Korro Bio

NasdaqCM:KRRO

US$320.9m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Aldeyra Therapeutics
과거 주가
현재 주가	US$5.50
52주 최고치	US$6.74
52주 최저치	US$1.42
베타	1.43
11개월 변경	-4.43%
3개월 변경 사항	69.23%
1년 변경 사항	-17.66%
33년 변화	-37.99%
5년 변화	-2.48%
IPO 이후 변화	-23.61%

최근 뉴스 및 업데이트

Recent updates

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?

Dec 22

주주 수익률

	ALDX	US Biotechs	US 마켓
7D	-6.6%	-2.9%	0.9%
1Y	-17.7%	18.9%	32.3%

수익률 대 산업: ALDX 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ALDX 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ALDX's price volatile compared to industry and market?
ALDX volatility
ALDX Average Weekly Movement	13.7%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

안정적인 주가: ALDX 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ALDX 의 주간 변동성( 12% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2004	10	Todd Brady	www.aldeyra.com

생명공학 회사인 알데이라 테라퓨틱스는 면역 매개 질환 치료제를 개발 및 상용화하는 회사입니다. 주요 제품 후보로는 안구건조증 치료를 위한 임상 3상 시험 중인 반응성 알데히드 종(RASP) 조절제인 레렉살랩이 있습니다. 또한 코로나19, 아토피성 천식, 건선, 알코올 중독 치료를 위한 경구용 RASP 조절제인 ADX-629와 염증과 시력 상실을 특징으로 하는 희귀 망막 질환인 망막색소변성증 치료를 위한 디하이드로폴산염 환원효소 억제제인 ADX-2191을 개발하고 있습니다.

Aldeyra Therapeutics, Inc. 기본 사항 요약

Aldeyra Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ALDX 기본 통계
시가총액	US$326.82m
수익(TTM)	-US$37.87m
수익(TTM)	n/a

0.0x

P/S 비율

-8.6x

P/E 비율

ALDX 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ALDX 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$37.87m
수익	-US$37.87m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.64
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	15.5%

ALDX 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ALDX 주식 개요

보상

위험 분석

Aldeyra Therapeutics, Inc. 경쟁사

NasdaqGS:INZY

US$325.0m

NasdaqGS:MGTX

US$329.7m

NasdaqGM:CRVS

US$322.1m

NasdaqCM:KRRO

US$320.9m

가격 내역 및 성능

최근 뉴스 및 업데이트

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

Recent updates

Chief Development Officer recently sold US$76k worth of stock

Chief Development Officer notifies of intention to sell stock

Price target increased by 8.1% to US$10.00

New minor risk - Share price stability

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Consensus EPS estimates fall by 209%

New minor risk - Profitability

No longer forecast to breakeven

Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Consensus EPS estimates upgraded to US$0.18 loss

Forecast to breakeven in 2026

Consensus EPS estimates fall by 163%

Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease

No longer forecast to breakeven

New minor risk - Profitability

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

New minor risk - Profitability

No longer forecast to breakeven

Forecast to breakeven in 2024

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease

CEO, President & Director recently sold US$581k worth of stock

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2024

New minor risk - Profitability

Forecast to breakeven in 2024

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Consensus revenue estimates increase by 55%

Consensus revenue estimates increase by 57%

Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis

Consensus revenue estimates increase by 600%

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Consensus revenue estimates decrease by 82%, EPS upgraded

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

New minor risk - Market cap size

New minor risk - Profitability

Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye Disease

Consensus revenue estimates decrease by 61%, EPS upgraded

Price target decreased by 13% to US$17.86

CEO, President & Director exercised options and sold US$492k worth of stock

Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, Inc

Consensus revenue estimates increase by 36%

Consensus revenue estimates decrease by 73%, EPS upgraded

Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, Inc

Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic Cough

Consensus revenue estimates increase by 15%

Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic Conjunctivitis

Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Consensus revenue estimates decrease by 41%, EPS upgraded

Price target increased by 8.4% to US$21.83

Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease Trials

Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease

Forecast to breakeven in 2025